Impax Asset Management Group plc Has $423.89 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Impax Asset Management Group plc grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 9.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,793,010 shares of the medical research company’s stock after buying an additional 157,809 shares during the period. IQVIA makes up 1.7% of Impax Asset Management Group plc’s portfolio, making the stock its 16th largest position. Impax Asset Management Group plc’s holdings in IQVIA were worth $423,885,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. QRG Capital Management Inc. boosted its holdings in shares of IQVIA by 2.1% in the third quarter. QRG Capital Management Inc. now owns 6,190 shares of the medical research company’s stock valued at $1,467,000 after buying an additional 130 shares during the period. Asset Management One Co. Ltd. boosted its stake in IQVIA by 1.3% in the 3rd quarter. Asset Management One Co. Ltd. now owns 71,077 shares of the medical research company’s stock worth $16,843,000 after purchasing an additional 888 shares during the period. National Pension Service raised its stake in shares of IQVIA by 12.7% during the 3rd quarter. National Pension Service now owns 435,067 shares of the medical research company’s stock worth $103,098,000 after purchasing an additional 49,130 shares in the last quarter. Intact Investment Management Inc. boosted its holdings in shares of IQVIA by 21.8% in the 3rd quarter. Intact Investment Management Inc. now owns 3,180 shares of the medical research company’s stock valued at $754,000 after buying an additional 570 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its holdings in IQVIA by 0.6% during the third quarter. Robeco Institutional Asset Management B.V. now owns 118,394 shares of the medical research company’s stock worth $28,056,000 after buying an additional 674 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on IQV shares. Deutsche Bank Aktiengesellschaft cut their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday. Evercore ISI lowered their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Barclays cut their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday. The Goldman Sachs Group decreased their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday. Finally, UBS Group raised their price target on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $261.56.

IQVIA Price Performance

NYSE:IQV traded up $0.13 during trading hours on Monday, reaching $209.29. 730,407 shares of the company were exchanged, compared to its average volume of 1,085,736. The company has a market capitalization of $38.15 billion, a P/E ratio of 27.55, a P/E/G ratio of 2.01 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.85. The business has a 50 day moving average of $234.31 and a 200 day moving average of $229.76. IQVIA Holdings Inc. has a 1-year low of $190.20 and a 1-year high of $261.73.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.